Press Releases Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 09:05:27 19/02/2026 GMT			5-day change	1st Jan Change
1,832.25 ^DKK	+0.40%		-2.60%	-9.62%

02-18	Genmab: 2025 miss and cautious 2026 targets erode investor confidence
02-18	DNB Carnegie Raises Target Price for Genmab to 2,300 Danish Kroner (from 2,235), Reiterates Buy Recommendation	FW

Press Releases

02-18	Notice to Convene the Annual General Meeting of Genmab A/S	GL
02-17	Genmab Announces Initiation of Share Buy-Back Program	GL
02-17	Genmab A/S : Investor Presentation - February 2026	PU
02-17	Genmab Files Annual Report with the U.S. Securities and Exchange Commission	GL
02-17	Genmab A/S : 2025 Full Year Financial Results Presentation	PU
02-17	Genmab A/S : Corporate Governance Report 2025	PU
02-17	Genmab A/S : 2025 Annual Report	PU
02-17	Genmab A/S : Compensation Report 2025	PU
02-17	Genmab Publishes 2025 Annual Report	GL
02-03	Genmab A/S : Articles of association dated January 29, 2026 – English	PU
02-03	Genmab A/S : has published its Articles of Association	PU
01-29	Grant of Restricted Stock Units and Warrants to Employees in Genmab	GL
01-21	Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025	GL
01-19	AbbVie Announces Topline Results for Epcoritamab (DuoBody(R) CD3xCD20) from Phase 3 EPCORE(R) DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	AQ
01-19	Genmab Announces Topline Results for Epcoritamab from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed, Refractory Diffuse Large B-cell Lymphoma	AQ
01-16	Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	BU
01-16	Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	GL
01-13	Genmab A/S : JP Morgan 2026 Presentation	PU
01-07	Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	BU
01-07	Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	GL
01-05	Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference	GL
12-29	Genmab Portfolio Prioritization Update	BU
12-29	Genmab Portfolio Prioritization Update	GL
12-22	Genmab A/S : Animal Welfare Policy	PU
12-19	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Genmab: 2025 miss and cautious 2026 targets erode investor confidence

February 18, 2026 at 02:09 pm

Genmab: From now on, courage to the most patient

April 01, 2025 at 03:57 pm